Legal & General Group
LGND icon

Legal & General Group’s Ligand Pharmaceuticals LGND Stock Holding History

Legal & General Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.5M Sell
97,660
-10,723
-10% -$2.12M ﹤0.01% 826
2025
Q4 		$20.5M Buy
108,383
+13
+0% +$2.5K ﹤0.01% 837
2025
Q3 		$19.2M Sell
108,370
-9,963
-8% -$1.48M ﹤0.01% 884
2025
Q2 		$13.5M Buy
118,333
+16,171
+16% +$1.73M ﹤0.01% 1031
2025
Q1 		$10.7M Buy
102,162
+44,324
+77% +$5.01M ﹤0.01% 1102
2024
Q4 		$6.2M Buy
57,838
+2,658
+5% +$300K ﹤0.01% 1465
2024
Q3 		$5.52M Buy
55,180
+8,045
+17% +$810K ﹤0.01% 1533
2024
Q2 		$3.97M Sell
47,135
-487
-1% -$38.8K ﹤0.01% 1643
2024
Q1 		$3.48M Buy
47,622
+148
+0.3% +$10.9K ﹤0.01% 1688
2023
Q4 		$3.39M Buy
47,474
+1,869
+4% +$110K ﹤0.01% 1704
2023
Q3 		$2.73M Sell
45,605
-1,652
-3% -$109K ﹤0.01% 1754
2023
Q2 		$3.41M Buy
47,257
+775
+2% +$58.1K ﹤0.01% 1670
2023
Q1 		$3.42M Sell
46,482
-250
-0.5% -$17.8K ﹤0.01% 1618
2022
Q4 		$3.12M Sell
46,732
-26,504
-36% -$1.72M ﹤0.01% 1664
2022
Q3 		$3.93M Sell
73,236
-4,501
-6% -$265K ﹤0.01% 1485
2022
Q2 		$4.33M Buy
77,737
+3,093
+4% +$176K ﹤0.01% 1485
2022
Q1 		$5.24M Sell
74,644
-692
-0.9% -$50.2K ﹤0.01% 1493
2021
Q4 		$7.26M Buy
75,336
+2,324
+3% +$215K ﹤0.01% 1378
2021
Q3 		$6.35M Buy
73,012
+30,161
+70% +$2.33M ﹤0.01% 1420
2021
Q2 		$3.51M Sell
42,851
-6,885
-14% -$573K ﹤0.01% 1720
2021
Q1 		$4.73M Buy
49,736
+13,263
+36% +$1.25M ﹤0.01% 1578
2020
Q4 		$2.26M Sell
36,473
-178
-0.5% -$10.1K ﹤0.01% 1838
2020
Q3 		$2.18M Buy
36,651
+781
+2% +$53.3K ﹤0.01% 1731
2020
Q2 		$2.5M Buy
35,870
+2,055
+6% +$130K ﹤0.01% 1638
2020
Q1 		$1.53M Sell
33,815
-5,763
-15% -$327K ﹤0.01% 1693
2019
Q4 		$2.58M Sell
39,578
-927
-2% -$61.9K ﹤0.01% 1673
2019
Q3 		$2.51M Buy
40,505
+2,690
+7% +$169K ﹤0.01% 1614
2019
Q2 		$2.69M Sell
37,815
-723
-2% -$53.3K ﹤0.01% 1564
2019
Q1 		$3.02M Buy
38,538
+2,830
+8% +$214K ﹤0.01% 1489
2018
Q4 		$3.02M Sell
35,708
-44,852
-56% -$4.78M ﹤0.01% 1360
2018
Q3 		$13.8M Buy
80,560
+5,867
+8% +$885K 0.01% 795
2018
Q2 		$9.67M Buy
74,693
+2,587
+4% +$289K 0.01% 848
2018
Q1 		$7.38M Buy
72,106
+4,475
+7% +$443K 0.01% 921
2017
Q4 		$5.78M Buy
67,631
+1,871
+3% +$162K ﹤0.01% 1011
2017
Q3 		$5.58M Buy
65,760
+5,765
+10% +$456K ﹤0.01% 972
2017
Q2 		$4.54M Buy
59,995
+6,458
+12% +$452K ﹤0.01% 1037
2017
Q1 		$3.53M Buy
53,537
+745
+1% +$49K ﹤0.01% 1138
2016
Q4 		$3.35M Buy
52,792
+25,028
+90% +$1.58M ﹤0.01% 1071
2016
Q3 		$1.77M Buy
27,764
+20,725
+294% +$1.52M ﹤0.01% 1121
2016
Q2 		$529K Buy
7,039
+550
+8% +$40.8K ﹤0.01% 1327
2016
Q1 		$433K Buy
6,489
+1,109
+21% +$67.4K ﹤0.01% 1370
2015
Q4 		$361K Hold
5,380
– – ﹤0.01% 1457
2015
Q3 		$290K Hold
5,380
– – ﹤0.01% 1513
2015
Q2 		$335K Sell
5,380
-931
-15% -$50.8K ﹤0.01% 1489
2015
Q1 		$300K Buy
6,311
+1,138
+22% +$43.6K ﹤0.01% 1486
2014
Q4 		$171K Sell
5,173
-192
-4% -$6.25K ﹤0.01% 1659
2014
Q3 		$157K Buy
+5,365
New +$178K ﹤0.01% 1623

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Legal & General Group's LGND Position: Q1 2026 in Review

Legal & General Group reduced its Ligand Pharmaceuticals (LGND) stake by 9.9% in Q1 2026, selling an estimated $2.12M and leaving 97,660 shares worth $19.5M. The position accounts for ﹤0.01% of the portfolio, ranked #826.

Legal & General Group first reported a position in LGND in Q3 2014 and has held it in 47 quarters since. The position peaked at $20.5M in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Legal & General Group held 97,660 shares of Ligand Pharmaceuticals worth $19.5M as of Q1 2026.
  • Legal & General Group sold 10,723 Ligand Pharmaceuticals shares in Q1 2026, an estimated $2.12M.
  • Ligand Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #826 holding.
  • Legal & General Group first reported a position in Ligand Pharmaceuticals in Q3 2014 and has held it in 47 quarters since.
  • Legal & General Group's Ligand Pharmaceuticals position peaked at $20.5M in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.